GS030-DP

Asset

Delivers a light-sensitive opsin to retinal ganglion cells, enabling responses to light stimulation.

Stage
Phase 1
Modality
Gene therapy
Target
Not known
1
Indication
1
Trial
1
Developer

Indications

1

In the full profile

  • Owner and partners1
  • Trials1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets